Peptide Therapeutics in Neurodegenerative Disorders
Neurodegenerative disorders, such as Alzheimer’s and Parkinson’s disease, are characterized by protein misfolding, neuronal loss, and cognitive decline. Peptide therapeutics can modulate these pathological processes by inhibiting aggregation, enhancing neuroprotection, and targeting specific receptors involved in neuronal signaling.
For example, amyloid-beta-targeting peptides are being developed to prevent plaque formation in Alzheimer’s disease. Peptides that mimic neurotrophic factors support neuronal survival, synaptic plasticity, and cognitive function. Delivery methods, including nanoparticles and intranasal administration, improve central nervous system penetration and therapeutic efficacy.
Peptide-based strategies offer a novel approach to these challenging diseases, providing hope for disease modification and improved patient outcomes.